about
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteersSingle and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteersDose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study.Pharmacokinetic comparison of sustained- and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteersPopulation pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysisA simple dosing scheme for intravenous busulfan based on retrospective population pharmacokinetic analysis in korean patientsProspective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric CancerInduction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers.Tolerability and pharmacokinetics of two formulations of megestrol acetate under fed conditions in healthy volunteers.Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence, crossover study.Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma.Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.Prediction of plasma caffeine concentrations in young adolescents following ingestion of caffeinated energy drinks: a Monte Carlo simulation.Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers.Predicting the efficacy of an oral paclitaxel formulation (DHP107) through modeling and simulation.Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteersInfluence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography.A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.Estimation of indocyanine green elimination rate constant k and retention rate at 15 min using patient age, weight, bilirubin, and albumin.Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: an open-label, randomized-sequence, three-treatment, three-way crosPopulation plasma and urine pharmacokinetics of ivabradine and its active metabolite S18982 in healthy Korean volunteers.The pharmacokinetics of letrozole: association with key body mass metrics.Modeling and simulation analysis of the relationship between lesion recurrence on brain images and clinical recurrence in patients with ischemic stroke.Pharmacokinetics and pharmacodynamics of propofol microemulsion and lipid emulsion after an intravenous bolus and variable rate infusion.Relationship between nurse staffing level and adult nursing-sensitive outcomes in tertiary hospitals of Korea: Retrospective observational study.Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women.Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies.Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers.Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil.
P50
Q33385128-A733DF39-212C-4DB2-A6B1-2544EAF70F6FQ34284529-DF00844A-2277-4047-9F36-B5A1F6676C2CQ34621613-7A4E0887-B1DA-416A-8BCD-059DFCF98D3FQ35136178-028379FB-7AED-43BC-8444-10C925886FF0Q35184995-91493F7E-1913-4E4C-92FF-BC675385966BQ35223225-B707305C-C514-4FDC-8FE8-6CCF413FAE5BQ35746830-0EF8298E-48D5-461C-8217-6E644E4D229FQ35849363-21E769D2-C60A-4679-A294-108C21B51A76Q36024494-751555B4-E43F-42AE-97BE-2652C547392BQ36166109-C43D2B0F-FDDE-493B-85B3-E002B209D20AQ36881201-756FC8E3-FED5-46F0-8B1A-F7FC80A6CD7BQ37672089-8FD98E39-2F24-4010-BCC6-77167C314F80Q38402255-6C4BF325-9D64-473A-8F24-BAB0CA2596A0Q38416038-58ABEDB9-7A68-4A8E-8A6D-9A8682190A8AQ38420059-F19A882B-0C9B-402A-8C3C-737576A1595EQ38472701-54B01BA5-8C27-4739-94FC-35E291028942Q38476926-AA681938-108C-4E65-B4C4-B204B8A0C458Q39208887-74614CC8-40B0-4854-8140-70AA6E558700Q40542006-57264916-0F33-412A-8A4E-CEE43FC15615Q40795226-D870DDAE-CF09-4687-977C-68647387C084Q40899039-6FF9ADA7-F7B6-4FC9-AC4E-93818242DB51Q41594623-1639D038-C1F9-4FB4-804F-B22C358BB4BFQ41958385-FD685848-EC69-468A-AA28-2B8E77403582Q42760208-AC5AF1BA-1F0F-43C8-837B-D6A7FCE80CA3Q44263865-66F6B46E-5661-4DB9-81EA-68553CF83362Q44324062-4CE4E16A-4A5C-4A68-9E62-E5D43CC06134Q44427695-9138EF77-E872-4621-A78F-39D7ADAACAC1Q45832829-6E8CCC5A-2911-4551-ACAF-9525B5BCD2E6Q45962757-26BCEDC3-1D02-4F73-B76A-BC3D3250ADD3Q46726099-61B6CBC6-C640-48A4-A8C5-8D2E6994C5EAQ47450225-E8F6B040-598E-465E-9B72-22F514A67D65Q48459513-9C81E03D-017E-4355-8498-37ECE6F3C21BQ48603059-68E45F2B-8288-41D7-A7A9-866575B0208FQ49894296-D9112805-538D-4E02-9B30-64AE3CD181CAQ51122693-FB0A6282-CD22-436E-A645-0733B500E167Q51313119-35A0B336-6B79-4647-BD51-A778CFD30E02Q51327511-F61CD774-19AD-4AC7-8D8B-496E55B9C73DQ51369105-603832ED-2AB1-4BA1-BD2D-1B6BA02C52EAQ52665414-BC5CBF59-95AC-4352-94BD-BFE195264027Q53079170-7A1A1FDF-2985-4F9A-A287-AC69110A10D2
P50
description
researcher ORCID ID = 0000-0001-7399-5879
@en
wetenschapper
@nl
name
Kyun-Seop Bae
@ast
Kyun-Seop Bae
@en
Kyun-Seop Bae
@es
Kyun-Seop Bae
@nl
type
label
Kyun-Seop Bae
@ast
Kyun-Seop Bae
@en
Kyun-Seop Bae
@es
Kyun-Seop Bae
@nl
prefLabel
Kyun-Seop Bae
@ast
Kyun-Seop Bae
@en
Kyun-Seop Bae
@es
Kyun-Seop Bae
@nl
P106
P1153
54960188400
P31
P496
0000-0001-7399-5879